Cell death

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
Thursday, March 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Survival, Survival rate, NSCLC, Associate, Cervical cancer, Medicine, Patient, Lung, University, MD, Lung cancer, AACR, University of Southern California, Vaccine

The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.

Key Points: 
  • The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.
  • Affinity tuned AIC100 is expected to selectively bind and kill tumor cells expressing cell surface ICAM-1 while sparing healthy cells.
  • “We are excited to share preclinical proof-of-concept data for our affinity-tuned CAR T program AIC100 in new solid tumor types.
  • “This promising preclinical data presented at AACR 2024 suggest that AIC100 could be a potential new option for patients with these ICAM-1-positive tumors.”

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

EQS-News: DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Retrieved on: 
Wednesday, March 13, 2024
Therapy, FDA, Patent, Bile, Spacecraft, Lung, GLP, Breast, Reactive oxygen species, Patient, Survival, Cell death, Melanoma, Pharmaceutical industry

DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Key Points: 
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    The issuer is solely responsible for the content of this announcement.
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no.
  • 11,890,350 (‘350) by the United States Patent and Trademark Office (USPTO), broadly covering its breakthrough AccuTOX® technology.
  • This patent marks the fourth granted US patent in Defence’s ever-growing patent portfolio, which currently incudes seven published patent families.

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
SAN, 23andMe, FDA, Cancer, AACR, Therapy, Genetics, NK, NKG2D, Cell death, Biology, IND, Vaccine

These presentations will be the first scientific communications the Company has prepared on ‘1473 since announcing its pursuit of this novel, genetically-validated target.

Key Points: 
  • These presentations will be the first scientific communications the Company has prepared on ‘1473 since announcing its pursuit of this novel, genetically-validated target.
  • Further, ‘1473 is Fc-effector enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells.
  • The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 5, 2024.
  • Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation

Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo

Retrieved on: 
Monday, March 4, 2024
TCR, Safety, Cell death, Brain, Liver cancer, Patent, Patient, Vaccine

--- end of press release ---

Key Points: 
  • “We are delighted with the receipt of the patent grant for our iM-TCR from the Japan Patent Office as we continue to expand and strengthen our IP portfolio.
  • The ability to control the level of TCR activity with our iM-TCR technology after dosing has the potential to deliver more individualized efficacy and safety for patients.
  • This patent grant is further validation of this innovative iM-TCR technology,” said Selwyn Ho, CEO at Medigene.
  • The iM-TCR technology modifies the TCR to achieve control of TCR surface expression, allowing for fine-tuning of activity against tumor cells and thereby reducing potential inflammatory responses in the body.

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

Retrieved on: 
Wednesday, February 28, 2024
Pyroptosis, Liver, Macrophage, Inflammation, Cell death, ASC, Cardiovascular disease, Cancer, NLRP3, Syndrome, WAT, Breast, Dyslipidemia, Therapy, Hypertension, Super Meat Boy, Insulin resistance, Adipose tissue, Inflammasome, Tissue, DSM-IV codes, Research, Pharmaceutical industry

Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.

Key Points: 
  • Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • WESTON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in Nature reinforcing IC 100’s rationale for inhibiting ASC and ASC Specks to attenuate damaging inflammation associated with various conditions, including obesity and its complications.
  • Likewise, IC 100 uniquely inhibits ASC specks to attenuate spread and perpetuation of damaging inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Head, Neoplasm, Neck, DAR, Toxicity, Therapeutic index, Cancer, Spacecraft, AACR, Lung, ADC, Annual general meeting, Breast, Safety, Stomach, Human, Ovarian cancer, Immunoglobulin G, Adenocarcinoma, Abstract, Patient, Poster, DNA repair, Translocase, Cell death, Biology, Cancer research, Esophagus, DNA, 5T4, Pharmaceutical industry

Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

Key Points: 
  • Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.
  • The results we will present at the AACR Annual Meeting will highlight the preclinical differentiation of our two lead candidates, TUB-030 and TUB-040.
  • The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR journal, Cancer Research.
  • The company will issue a press release detailing the full preclinical data following the presentation at AACR.

Global Bicycle Toxin Conjugates Clinical Trials Insight 2024 - Bicycle Therapeutics Emerges as a Trailblazer, Leading the Novel Development of Bicycle Toxin Conjugates for Cancer Therapy - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024
Pharmaceutical, Health, Oncology, Therapy, Research, Indication, Hope, Peptide, Medicine, Patient, Cell death, Cancer, Pharmaceutical industry

The "Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Bicycle toxin conjugates, which are a seamless combination of bicyclic peptides and potent cytotoxic drugs, are at the forefront of therapeutics development.
  • Bicycle Therapeutics emerges as a trailblazer, leading the novel development of bicycle toxin conjugates for cancer therapy.
  • Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
    Clinical Research & Market Trends by Region: US, UK & EU
    Comprehensive Insight on All Drugs in the Clinical Pipeline by Company, Indication & Phase